FONTEYNE PAUL R. — SEC Form 4 Insider Trading Activity
Summary
Updated Jul 16, 2026
FONTEYNE PAUL R. has filed 2 SEC Form 4 filings across 2 companies in the last 90 days.
Profile
Paul R. Fonteyne is identified as a director of Apellis Pharmaceuticals, Inc. in the company's SEC filing with CIK 0001727550, the most recent filing dated January 5, 2026. Apellis is a commercial-stage biopharmaceutical company focused on developing therapies that inhibit the complement system, particularly at C3, to treat diseases with high unmet needs. Based on the SEC context, Fonteyne serves on Apellis' board as of the latest disclosure.
Role
Insider
Notability
40/100
Board memberships
Apellis Pharmaceuticals, Inc.
Awards & honors
Board member of Apellis Pharmaceuticals, Inc.
Contributes governance and strategic oversight to the company's leadership
Paul R. Fonteyne is identified as a director of Apellis Pharmaceuticals, Inc. in the company's SEC filing with CIK 0001727550, the most recent filing dated January 5, 2026. Apellis is a commercial-stage biopharmaceutical company focused on developing therapies that inhibit the complement system, particularly at C3, to treat diseases with high unmet needs. Based on the SEC conte…
How many SEC Form 4 filings has FONTEYNE PAUL R. submitted recently?
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Where can I see all of FONTEYNE PAUL R.'s SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
